Vascular Pharmaceuticals
Manufacturing · North Carolina, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
510 Meadowmont Village Cir Ste 283, Chap...Phone Number
(508) 362-3087Website
www.vascularpharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Vascular Pharmaceuticals
Vascular Pharmaceuticals is dedicated to addressing the complications of diabetes, specifically focusing on diabetic nephropathy, a common kidney disease among individuals with Type 1 and Type 2 diabetes. The company is pioneering a new treatment approach with its lead candidate, VPI-2690B, which is currently in Phase 2 clinical trials. Research indicates that VPI-2690B may halt and potentially reverse the progression of diabetic nephropathy, offering hope to those with limited treatment options. Their mission is to help people with diabetes lead longer, healthier lives.Explore more
Vascular Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Vascular Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Vascular Pharmaceuticals is spiking on competitors!
Earning: See what the market has to say on Vascular Pharmaceuticals recently announced quarterly report
Vascular Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Vascular Pharmaceuticals launches new products
Funding: Get notified immidiatlly once Vascular Pharmaceuticals has new funding data
Check if Vascular Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Vascular Pharmaceuticals
Click to see if Vascular Pharmaceuticals had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Vascular Pharmaceuticals as Masked Content
Find 3 more new buyers
Compare Similar Companies to Vascular Pharmaceuticals
Compare insights from companies similar to Vascular Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Vascular Pharmaceuticals
<$5M
1-10
Private
$13M
2005
BL
Bonnie LaymanChief Financial Officer, Consulting
Company Profile Activity
Activity Insights
Vascular Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Vascular Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Vascular Pharmaceuticals.
Vascular Pharmaceuticals financials insights
Gather financial insights about Vascular Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Debt
$1M
2015
Series A
$9M
2016
Debt
$3M
Vascular Pharmaceuticals Tech Stack
A closer look at the technologies used by Vascular Pharmaceuticals
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Vascular Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Vascular Pharmaceuticals is dedicated to addressing the complications of diabetes, specifically focusing on diabetic nephropathy, a common kidney disease among individuals with Type 1 and Type 2 diabetes. The company is pioneering a new treatment approach with its lead candidate, VPI-2690B, which is currently in Phase 2 clinical trials. Research in... Read More
